Fertility and Sterility
Volume 94, Issue 3 , Pages 841-849 , August 2010

The growth hormone–releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line

  • Marta Annunziata, Ph.D.

      Affiliations

    • Laboratory of Molecular and Cellular Endocrinology, Department of Internal Medicine, University of Turin, Turin, Italy
    • Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy
    • ,
  • Cristina Grande

      Affiliations

    • Laboratory of Molecular and Cellular Endocrinology, Department of Internal Medicine, University of Turin, Turin, Italy
    • Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy
    • ,
  • Francesca Scarlatti, Ph.D.

      Affiliations

    • Laboratory of Molecular and Cellular Endocrinology, Department of Internal Medicine, University of Turin, Turin, Italy
    • Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy
    • ,
  • Francesco Deltetto, M.D.

      Affiliations

    • Ginteam, Unit of Minimally Invasive Gynecology, Turin, Italy
    • ,
  • Elena Delpiano, M.D.

      Affiliations

    • Ginteam, Unit of Minimally Invasive Gynecology, Turin, Italy
    • ,
  • Marco Camanni, M.D.

      Affiliations

    • Ginteam, Unit of Minimally Invasive Gynecology, Turin, Italy
    • ,
  • Ezio Ghigo, M.D.

      Affiliations

    • Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy
    • ,
  • Riccarda Granata, Ph.D.

      Affiliations

    • Laboratory of Molecular and Cellular Endocrinology, Department of Internal Medicine, University of Turin, Turin, Italy
    • Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy
    • Corresponding Author InformationReprint requests: Riccarda Granata, Ph.D., Laboratory of Molecular and Cellular Endocrinology, Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Corso Dogliotti 14, 10126 Turin, Italy (FAX: (+39) 011 664 74 21).

Received 8 January 2009 ,Revised 24 March 2009 ,Accepted 26 March 2009.

References 

  1. Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364:1789–1799
  2. Gebel HM, Braun DP, Tambur A, Frame D, Rana N, Dmowski WP. Spontaneous apoptosis of endometrial tissue is impaired in women with endometriosis. Fertil Steril. 1998;69:1042–1047
  3. Noble LS, Simpson ER, Johns A, Bulun SE. Aromatase expression in endometriosis. J Clin Endocrinol Metab. 1996;81:174–179
  4. Jones RK, Bulmer JN, Searle RF. Immunohistochemical characterization of proliferation, oestrogen receptor and progesterone receptor expression in endometriosis: comparison of eutopic and ectopic endometrium with normal cycling endometrium. Hum Reprod. 1995;10:3272–3279
  5. Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone–releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218:585–587
  6. Shibasaki T, Kiyosawa Y, Masuda A, Nakahara M, Imaki T, Wakabayashi I, et al. Distribution of growth hormone–releasing hormone–like immunoreactivity in human tissue extracts. J Clin Endocrinol Metab. 1984;59:263–268
  7. Christofides ND, Stephanou A, Suzuki H, Yiangou Y, Bloom SR. Distribution of immunoreactive growth hormone–releasing hormone in the human brain and intestine and its production by tumors. J Clin Endocrinol Metab. 1984;59:747–751
  8. Chatzistamou I, Schally AV, Pafiti A, Kiaris H, Koutselini H. Expression of growth hormone–releasing hormone in human primary endometrial carcinomas. Eur J Endocrinol. 2002;147:381–386
  9. Fu L, Osuga Y, Yano T, Takemura Y, Morimoto C, Hirota Y, et al. Expression and possible implication of growth hormone–releasing hormone receptor splice variant 1 in endometriosis. Fertil Steril. Published online August 5, 2008 [Epub ahead of print].
  10. Kahan Z, Arencibia JM, Csernus VJ, Groot K, Kineman RD, Robinson WR, et al. Expression of growth hormone–releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab. 1999;84:582–589
  11. Khorram O, Garthwaite M, Grosen E, Golos T. Human uterine and ovarian expression of growth hormone–releasing hormone messenger RNA in benign and malignant gynecologic conditions. Fertil Steril. 2001;75:174–179
  12. Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, et al. The expression of the pituitary growth hormone–releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci U S A. 2005;102:17424–17429
  13. Rekasi Z, Czompoly T, Schally AV, Halmos G. Isolation and sequencing of cDNAs for splice variants of growth hormone–releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A. 2000;97:10561–10566
  14. Barabutis N, Schally AV. Knocking down gene expression for growth hormone–releasing hormone inhibits proliferation of human cancer cell lines. Br J Cancer. 2008;98:1790–1796
  15. Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone–releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab. 2008;4:33–43
  16. Kiaris H, Chatzistamou I, Schally AV, Halmos G, Varga JL, Koutselini H, et al. Ligand-dependent and -independent effects of splice variant 1 of growth hormone–releasing hormone receptor. Proc Natl Acad Sci U S A. 2003;100:9512–9517
  17. Garcia-Fernandez MO, Schally AV, Varga JL, Groot K, Busto R. The expression of growth hormone–releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat. 2003;77:15–26
  18. Rekasi Z, Czompoly T, Schally AV, Boldizsar F, Varga JL, Zarandi M, et al. Antagonist of growth hormone–releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway. Proc Natl Acad Sci U S A. 2005;102:3435–3440
  19. Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling. Int J Cancer. 2004;112:570–576
  20. Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, et al. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-Jun intracellular signalling. Eur J Cancer. 2005;41:2735–2744
  21. Engel JB, Keller G, Schally AV, Toller GL, Groot K, Havt A, et al. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone–releasing hormone. J Clin Endocrinol Metab. 2005;90:3614–3621
  22. Keller G, Schally AV, Groot K, Toller GL, Havt A, Koster F, et al. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone–releasing hormone. Proc Natl Acad Sci U S A. 2005;102:10628–10633
  23. Szepeshazi K, Schally AV, Groot K, Armatis P, Hebert F, Halmos G. Antagonists of growth hormone–releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours. Eur J Cancer. 2000;36:128–136
  24. Krikun G, Mor G, Alvero A, Guller S, Schatz F, Sapi E, et al. A novel immortalized human endometrial stromal cell line with normal progestational response. Endocrinology. 2004;145:2291–2296
  25. Hapangama DK, Turner MA, Drury JA, Quenby S, Saretzki G, Martin-Ruiz C, et al. Endometriosis is associated with aberrant endometrial expression of telomerase and increased telomere length. Hum Reprod. 2008;23:1511–1519
  26. Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V, et al. Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes. 2008;57:967–979
  27. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone–releasing hormone. Mol Endocrinol. 1992;6:1734–1744
  28. Pombo CM, Zalvide J, Gaylinn BD, Dieguez C. Growth hormone–releasing hormone stimulates mitogen-activated protein kinase. Endocrinology. 2000;141:2113–2119
  29. Koster F, Engel JB, Schally AV, Honig A, Schroer A, Seitz S, et al. Triple-negative breast cancers express receptors for growth hormone–releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Breast Cancer Res Treat. 2008;
  30. Lania A, Filopanti M, Corbetta S, Losa M, Ballare E, Beck-Peccoz P, et al. Effects of hypothalamic neuropeptides on extracellular signal–regulated kinase (ERK1 and ERK2) cascade in human tumoral pituitary cells. J Clin Endocrinol Metab. 2003;88:1692–1696
  31. Csernus VJ, Schally AV, Kiaris H, Armatis P. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone–releasing hormone in vitro. Proc Natl Acad Sci U S A. 1999;96:3098–3103
  32. Szepeshazi K, Schally AV, Groot K, Armatis P, Halmos G, Herbert F, et al. Antagonists of growth hormone–releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer. 2000;82:1724–1731
  33. Gallego R, Pintos E, Garcia-Caballero T, Raghay K, Boulanger L, Beiras A, et al. Cellular distribution of growth hormone–releasing hormone receptor in human reproductive system and breast and prostate cancers. Histol Histopathol. 2005;20:697–706
  34. Johnson MC, Torres M, Alves A, Bacallao K, Fuentes A, Vega M, et al. Augmented cell survival in eutopic endometrium from women with endometriosis: expression of c-Myc, TGF-beta1 and Bax genes. Reprod Biol Endocrinol. 2005;3:45
  35. Rekasi Z, Varga JL, Schally AV, Halmos G, Armatis P, Groot K, et al. Antagonists of growth hormone–releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. Endocrinology. 2000;141:2120–2128
  36. Rekasi Z, Varga JL, Schally AV, Plonowski A, Halmos G, Csernus B, et al. Antiproliferative actions of growth hormone–releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways. Peptides. 2001;22:879–886
  37. Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A, Kiaris H. Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone–releasing hormone receptor. Proc Natl Acad Sci U S A. 2007;104:5575–5579
  38. Kovacs M, Schally AV, Lee EJ, Busto R, Armatis P, Groot K, et al. Inhibitory effects of antagonistic analogs of GHRH on GH3 pituitary cells overexpressing the human GHRH receptor. J Endocrinol. 2002;175:425–434
  39. Csernus V, Schally AV, Groot K. Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro. Peptides. 1999;20:843–850
  40. Busto R, Schally AV, Varga JL, Garcia-Fernandez MO, Groot K, Armatis P, et al. The expression of growth hormone–releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci U S A. 2002;99:11866–11871
  41. Stork PJ, Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 2002;12:258–266
  42. Yoshino O, Osuga Y, Hirota Y, Koga K, Hirata T, Harada M, et al. Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis. Am J Reprod Immunol. 2004;52:306–311
  43. Gentilini D, Busacca M, Di Francesco S, Vignali M, Vigano P, Di Blasio AM. PI3K/Akt and ERK1/2 signalling pathways are involved in endometrial cell migration induced by 17beta-estradiol and growth factors. Mol Hum Reprod. 2007;13:317–322
  44. Murk W, Atabekoglu CS, Cakmak H, Heper A, Ensari A, Kayisli UA, et al. Extracellularly signal-regulated kinase activity in the human endometrium: possible roles in the pathogenesis of endometriosis. J Clin Endocrinol Metab. 2008;93:3532–3540
  45. Kiaris H, Schally AV, Varga JL. Suppression of tumor growth by growth hormone–releasing hormone antagonist JV-1-36 does not involve the inhibition of autocrine production of insulin-like growth factor II in H-69 small cell lung carcinoma. Cancer Lett. 2000;161:149–155

 M.A. has nothing to disclose. C.G. has nothing to disclose. F.S. has nothing to disclose. F.D. has nothing to disclose. E.D. has nothing to disclose. M.C. has nothing to disclose. E.G. has nothing to disclose. R.G. has nothing to disclose.

 Supported by grants from the Regione Piemonte (2006 and 2008 to E.G.; 2008 to R.G.) and the University of Turin (2006 to E.G; 2007 and 2008 to E.G. and R.G.) and by Ginteam (Turin, Italy).

PII: S0015-0282(09)00763-8

doi: 10.1016/j.fertnstert.2009.03.093

Fertility and Sterility
Volume 94, Issue 3 , Pages 841-849 , August 2010

Article Tools

* Image Usage & Resolution